An audience with...Francis Collins. Interviewed by Asher Mullard.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed.

1. AΙ-Driven Drug Repurposing: Applications and Challenges.Medicines (Basel, Switzerland) · 2025
   Review
2. Repositioning Drugs for Rare Diseases Based on Biological Features and Computational Approaches.Healthcare (Basel, Switzerland) · 2022
   Article
3. High throughput screening in duchenne muscular dystrophy: from drug discovery to functional genomics.Biology · 2014
   Review
4. Lost but making progress--Where will new analgesic drugs come from?Science translational medicine · 2014
   Review
5. Rare diseases research: expanding collaborative translational research opportunities.Chest · 2013
   Article
6. Connecting the dots in translational research.Nature reviews. Drug discovery · 2012
   Article
7. Teach-Discover-Treat (TDT): collaborative computational drug discovery for neglected diseases.Journal of molecular graphics & modelling · 2012
   Article
8. The prevalence and cost of unapproved uses of top-selling orphan drugs.PloS one · 2012
   Article
9. The NIH translational research center might trade public risk for private reward.Nature medicine · 2011
   Article
10. Medicinal chemistry for 2020.Future medicinal chemistry · 2011
    Article
11. An empirical review of major legislation affecting drug development: past experiences, effects, and unintended consequences.The Milbank quarterly · 2011
    Review
12. An NIH National Center for Advancing Translational Sciences: is a focus on drug discovery the best option?Nature reviews. Drug discovery · 2011
    Article

Corrections and comments

• Commented on by
  An NIH National Center for Advancing Translational Sciences: is a focus on drug discovery the best option?2011

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as